Debiopharm buys Immunexpress
07.03.2014 - Debiopharm seeks to expand and invests US$6m into molecular diagnostic company Immunexpress for the development of their sepsis diagnostic
Sepsis expert Immunexpress Group has secured US$6m from a financing round led by Debiopharm Group. The money will be used to advance development and commercialisation of Immunexpress' late-stage sepsis diagnostic product. The test quantifies multiple specific molecular markers from the patient's immune system for earlier diagnosis, detection, severity assessment and optimal targeting of drugs and other therapies. Immunexpress is a privately-held group of companies with locations in Brisbane, Australia and Seattle, USA.
"The early detection of sepsis is critical. This revolutionary technology will utilise the early immune response to sepsis and potentially lead to a more targeted treatment approach for each patient, which may provide better outcomes for the patients who present with this life-threatening condition," said Debiopharm board member Thierry Mauvernay.
Debiopharm Diagnostics SA is part of the Debiopharm Group, a Swiss-based global biopharmaceutical group of four companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investments. Back in 2012 Debiopharm – together with fellow Swiss Biocartis SA – forged a collaboration with Immunexpress and invested $2m in the company.
The Debiopharm Group has also announced that it is aiming to expand activities at Debiopharm Research & Manufacturing S.A., its industrial development and production facility in Martigny (Switzerland), through acquisition of industrial high-value added activities or companies in the pharmaceutical, biotech or medtech field. In the past, Debiopharm has signed licencing agreements with Roche and Novartis.